Advanced search
Publication Cover
Cancer Biology & Therapy Volume 19, 2018 - Issue 7
Submit an article Journal homepage
1,490
Views
2
CrossRef citations to date
0
Altmetric
Research Paper

Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies

Anthony R. MatoLeukemia Service, Division of Hematologic Oncology, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United StatesView further author information
, MD, MSCE,
Jennifer C. SampAbbVie, Inc., North Chicago, IL, United StatesCorrespondence[email protected]
View further author information
, PharmD, PhD,
Geneviève GauthierAnalysis Group, Inc., Montreal, Quebec, CanadaView further author information
, MSc,
Emi TerasawaAnalysis Group, Inc., New York, United StatesView further author information
, PhD &
Danielle M. BranderDivision of Hematologic Malignancies & Cellular Therapy, Duke University, Durham, NC, United StatesView further author information
, MD
Pages 636-643 | Received 06 Feb 2018, Accepted 03 Mar 2018, Published online: 30 Apr 2018

References

  • Owen C, Assouline S, Kuruvilla J, Uchida C, Bellingham C, Sehn L. Novel therapies for chronic lymphocytic leukemia: A Canadian perspective. Clin Lymphoma Myeloma Leuk. 2015;15(11):627–634.e625. doi:10.1016/j.clml.2015.07.649
  • U.S. Food and Drug Administration. Zydelig (idelalisib) Tablets, Drug Apporval Package; 2014 [Accessed 5 October 2017]. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206545Orig1s000TOC.cfm
  • U.S. Food and Drug Administration. Imbruvica (ibrutinib) Capsules, Drug Approval Package; 2015 [Accessed 5 Oct 2017]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205552Orig2s000TOC.cfm
  • Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42. doi:10.1056/NEJMoa1215637
  • Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007. doi:10.1056/NEJMoa1315226
  • Burger JA, Ghia P, Polliack A, Tam C, Suri D, Clow F, Kraljevic S, James D, Kipps TJ. Randomized, multicenter, open-label, phase III study of the BTK inhibitor ibrutinib versus chlorambucil in patients 65 years or older with treatment-naive CLL/SLL (RESONATE-2, PCYC-1115-CA). J Clin Oncol. 2013;31(15 suppl):TPS7130–TPS7130. doi:10.1200/jco.2013.31.15_suppl.tps7130
  • Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, George B, James D, Kantarjian H, Burger J, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015;125(13):2062–7. doi:10.1182/blood-2014-09-603670
  • Jain P, Thompson PA, Keating M, Estrov Z, Ferrajoli A, Jain N, Kantarjian H, Buggy JJ, O'Brien S, Wierda W. Causes of Discontinuation and Long-Term Outcomes of Patients with CLL after Discontinuing Ibrutinib. Blood. 2016;128(22):4390
  • Jain P, Thompson PA, Keating M, Estrov Z, Ferrajoli A, Jain N, Kantarjian H, Burger JA, O'Brien S, Wierda WG. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer. 2017;123(12):2268–73. doi:10.1002/cncr.30596
  • Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, et al. Etiology of Ibrutinib therapy discontinuation and outcomes in patients with chronic Lymphocytic Leukemia. JAMA Oncol. 2015;1(1):80–87. doi:10.1001/jamaoncol.2014.218
  • Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Ann Oncol. 2017;28(5):1050–6. doi:10.1093/annonc/mdx031
  • Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, et al. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood. 2016;128(18):2199–205. doi:10.1182/blood-2016-05-716977
  • Forum UC. Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients. Haematologica. 2016;101(12):1563–72. doi:10.3324/haematol.2016.147900
  • Jones JA, Wierda W, Choi MY, Davids MD, Cheson BD, Furman RR. Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib. J Clin Oncol. 2016;34(15 suppl):7519. doi:10.1200/JCO.2016.34.15_suppl.7519
  • Barr PM, Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Mulligan SP, Jaeger U, Furman RR, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017;129(19):2612–5. doi:10.1182/blood-2016-12-737346

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.